Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background We analysed the effect of ivabradine on outcomes in heart failure (HF) patients on recommended background therapies with heart rates ≥75 bpm and <75 bpm in the SHIFT trial. A cut-off value of ≥75 bpm was chosen by the EMEA for approval for the use of ivabradine in chronic heart failure.Methods The SHIFT population was divided by baseline heart rate ≥75 or <75 bpm. The effect of ivabradine was analysed for primary composite endpoint (cardiovascular death or HF hospitalization) and other endpoints.Results In the ≥75 bpm group, ivabradine reduced primary endpoint (HR 0.76, 95 % CI 0.68-0.85, P < 0.0001), all-cause mortality (HR 0.83, 95 % CI, 0.72-0.96, P = 0.0109), cardiovascular mortality (HR 0.83, 95 % CI, (0.71-0.97, P = 0.0166), HF death (HR 0.61, 95 % CI, 0.46-0.81, P < 0.0006), and HF hospitalization (HR 0.70, 95 % CI, 0.61-0.80, P < 0.0001). Risk reduction depended on heart rate after 28 days, with the best protection for heart rates <60 bpm or reductions >10 bpm. None of the endpoints was significantly reduced in the <75 bpm group, though there were trends for risk reductions in HF death and hospitalization for heart rate <60 bpm and reductions >10 bpm. Ivabradine was tolerated similarly in both groups.Conclusion The effect of ivabradine on outcomes is greater in patients with heart rate ≥75 bpm with heart rates achieved <60 bpm or heart rate reductions >10 bpm predicting best risk reduction. Our findings emphasize the importance of identification of high-risk HF patients by high heart rates and their treatment with heart rate-lowering drugs such as ivabradine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that most titration of β-blockade occurs early in the course of treatment, with most of the heart rate reduction occurring at < 50% of target dose.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [62]
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationCleland, J. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,549
Böhm, M., Swedberg, K., Komajda, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,099
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Kolloch, R., Legler, U. F., Champion, A., Cooper-DeHoff, R. M., Handberg, E., Zhou, Q., & Pepine, C. J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehn123 · Cited by 330
Conway, M. A., Allis, J., Ouwerkerk, R., Niioka, T., Rajagopalan, B., & Radda, G. K. (1991) · The Lancet · doi:10.1016/0140-6736(91)91838-l · Cited by 322
Tardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr311 · Cited by 300
Self-citationMulder, P., Barbier, S., Chagraoui, A., Richard, V., Henry, J. P., Lallemand, F., Renet, S., Lerebours, G., Mahlberg-Gaudin, F., & Thuillez, C. (2004) · Circulation · doi:10.1161/01.cir.0000118464.48959.1c · Cited by 294
Current-dependent Block of Rabbit Sino-Atrial Node If Channels by Ivabradine
Bucchi, A., Baruscotti, M., & DiFrancesco, D. (2002) · The Journal of General Physiology · doi:10.1085/jgp.20028593 · Cited by 289
Custodis, F., Baumhäkel, M., Schlimmer, N., List, F., Gensch, C., Böhm, M., & Laufs, U. (2008) · Circulation · doi:10.1161/circulationaha.107.746537 · Cited by 263
Self-citation
Cited by
Items 201–250 of 250
Desingu, R., Kaore, S. N., Kandelwal, G., & Balakrishnan, S. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00500-7 · Cited by 1
“Adequate control of heart rate decreases the incidence of MACE and the frequency of hospitalization [7].”
BackgroundThe Endpoint on Measuring the Clinical Effects of Renal Denervation: What Are the Best Surrogates
Sobotka, P. A., Harrison, D. G., & Fudim, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5223-1_4 · Cited by 1
Heart failure units: State of the art in disease management
Timóteo, A. T., Pereira‐da‐Silva, T., Moreira, R. I., Gonçalves, A., Soares, R. M., & Ferreira, F. (2020) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2020.02.008 · Cited by 2
Optimisation of Pacemaker Therapy for Cardiac Function
Gierula, J. (2017) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Exploring the force-frequency relationship in people with chronic heart failure
Lowry, J. E. (2021) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Nuevas evidencias en Insuficiencia Cardiaca con Ivabradina
Roman, A. V. (2012) · Galicia Clínica · doi:10.22546/20/368
“El que no existan datos sobre este grupo de pacientes en los que actualmente la ivabradina está indicada, ha llevado a que se realice un análisis en profundidad de los resultados en el subgrupo de pacientes con FC basal 75 lpm, que se ha publicado recientemente((16)).”
BackgroundAntiarrhythmic properties of novel antianginal drugs in dog and human cardiac preparations
Szél, T. (2013) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.1897
“for the treatment of heart failure or myocardial infarction is expected [73-86].”
BackgroundIvabradine: a guide to its use in chronic heart failure
Keating, G. M., & Perry, C. M. (2014) · Drugs & Therapy Perspectives · doi:10.1007/s40267-014-0109-5
“with a baseline heart rate of C75 beats per min, the greatest risk reductions were seen in patients who achieved a heart rate of \60 beats per min or a heart rate reduction of [10 beats per min at 28 days [16].”
BackgroundHere Comes a Novel Heart-Rate Reducing Therapy in Heart Failure Treatment
Watanabe, T. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0054
Pinto, F. J. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv057
“The results of the recent INTENSIFY study confirmed clinical efficacy of ivabradine in daily practice over a 4-month periodin1956patientswithCHF.25After4months, ivabradine had reducedHR by18.”
ResultInfluentialIvabradine: a SHIFT in heart failure management
Sasidharan, D. (2016) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2016.11.3.118
Almanah 2013.: zatajivanje srca Almanac 2013: heart failure
Clark, A. L. (2013)
Rola iwabradyny w leczeniu niewydolności serca — stan wiedzy na rok 2014
Kasprzak, J. D. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0069
“5) [27]! Co bardzo ważne, przy współstosowaniu b-adrenolityku jego dawka nie determinuje korzyści z dołączenia iwabradyny — decydujące znaczenie ma wyjściowo osiągnięta częstotliwość pracy serca [28].”
Iwabradyna — lek dla współczesnego pacjenta z niewydolnością serca
Szymański, F. M. (2015) · Folia Cardiologica · doi:10.5603/fc.2015.0058
van Buuren, F., Fründ, A., Bogunović, N., Horstkotte, D., & Mellwig, K. (2016) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(16)31488-7
“risk for cardiovascular death of CHF-induced hospital admission by 16 % [45].”
BackgroundHeart Rate Modulation in Heart Failure
Chatterjee, N. A., & Lewis, G. D. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.043
Альманах-2013: cерцева недостатність *
Hill, C. (2014)
Is Heart Rate a Norepiphenomenon in Heart Failure?
Hensey, M., & O’Neill, J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0764-3
To Breathe, or Not to Breathe: That Is the Question
Mirizzi, G., Giannoni, A., Passino, C., & Emdin, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-26354-0_9
So lässt sich das Herz stärken
Vogt, A., & Frantz, S. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-9590-9
Chronische Herzinsuffizienz: Strukturierte Versorgung auf verschiedenen Stufen
Pflaumbaum, A. (2018) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2018.03.30.03
Macedo, L. G. R., Kosmidou, I., Crowley, A., Alu, M. C., Praz, F., Chen, S., Nazif, T. M., Babaliaros, V. C., Herrmann, H. C., Kapadia, S. R., et al. (2018) · Structural Heart · doi:10.1080/24748706.2018.1499060
Current Treatments for Heart Failure
Yıldırım, N. (2018) · Open Access Journal of Cardiology · doi:10.23880/oajc-16000118
“Ivabradine in HFrEF patients with left ventricle EF ≤35% and in sinus rhythm with a resting heart rate ≥75 bpm, was shown to provide a survival benefit [11].”
BackgroundDoes nitric oxide mediate effects of ivabradine in a failing heart?
Ma̧czewski, M. (2018) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2018.61819
“confer a survival benefit in a subgroup analysis of this patient population (2).”
BackgroundClark, A. (2014) · Srce i krvni sudovi · doi:10.5937/siks1404273c
So stützen Sie ein schwaches Herz: Chronische Herzinsuffizienz
Nowak, B. (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-2124-1
“bei denen die Ruhefrequenz unter erapie um mindestens 10/min sinkt [5].”
Recently Approved Pharmacologic Agents to Improve Outcomes in Heart Failure
Booth, D. C., & Rajagopalan, N. (2019) · Contemporary cardiology · doi:10.1007/978-3-030-19131-3_8
Chronic heart failure: actual aspects of treatment in real clinical practice
Трухан, Д. И., & Davydov, E. L. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-16-50-58
Pharmacological treatment of chronic heart failure with reduced left ventricular ejection fraction
Kucio, E. B. (2019) · Farmacja Polska · doi:10.32383/farmpol/116258
Bosco‐Lévy, P. (2019) · theses.fr (ABES) · doi:10.70675/a9226a3az0344z45f4za7fazac31b3228af1 · Cited by 1
Sakubitril/valsartan’ın diğer kalp yetersizliği tedavilerine göre mortalite yararı ne kadar farklı?
Arslan, M. (2020) · Updates in Cardiology · doi:10.5543/ucard.2020.80774
“0109) nisbi risk azalması sağladığı gösterilmiştir.[25]”
BORER, J. S., Kansal, A. R., Dorman, E. D., Krotneva, S., Zheng, Y., Patel, H., Tavazzi, L., Michel Komajda, N., Ford, I., Böhm, M., et al. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.9.1068
Self-citationCowie, M. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780198766223.003.0054
Kronik Kalp Yetersizliğinin Kanıta Dayalı Tedavisi
Selçuk, M. T., & Selçuk, H. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1369
Chan, Y., Cheung, B. M. Y., & Tse, H. (2022) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1487
Heart Failure Management in Developing Countries
Siddique, A., Otaibi, F. M., & Khan, S. F. (2023) · Springer eBooks · doi:10.1007/978-3-030-74786-2_6-1
Endpoints for Clinical Effects of Renal Denervation: What Is the Best Surrogate?
Friede, K. A., Fudim, M., & Sobotka, P. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_6
Ivabradine: sinus rhythm control in heart failure
Barillà, F., Carbonaro, M., kindy, S. A., & Mangieri, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822972-9.00041-9
Gliflozins, a new hope for heart failure? systematic review
Brustolin, A. B. G., & Porcile, R. (2023) · SCT Proceedings in Interdisciplinary Insights and Innovations. · doi:10.56294/piii2023166
Ivabradine and Milrinone—Bridge to Recovery in New HFrEF With Low‐Output Heart Failure
Racharla, L., GITZEL, L., Joseph, M., Guthier, D. G., & Hawwa, N. (2024) · Case Reports in Cardiology · doi:10.1155/2024/5278240
“In such situations, it is important to determine the “ super responders ” who derive the largest bene fi t. Data from the original SHIFT trial as well as a subsequent subgroup analysis showed larger bene fi ts with a higher resting HR of > 77 bpm [5] or > 75 bpm [6].”
BackgroundLauder, L., Pfister, O., & Mahfoud, F. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3513
PLAN DE CUIDADOS PARA UN PACIENTE CON DESCOMPENSACIÓN AGUDA DE INSUFICIENCIA CARDÍACA.
Pérez, L. C., Josa, P. P. T., Salas, P. L., Vilar, L. I., Bernal-Quirós, M. C. C., & Meneses, M. J. R. (2025) · Revista sanitaria de investigación. · doi:10.34896/rsi.2025.48.11.001
Historical aspects and current advances in pharmacological therapy for chronic heart failure
Kuchmin, A. N., Chernyakhovskay, A. A., & Tanich, A. V. (2025) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma640805
Kurgansky, K. E., Schubert, P., Parker, R., Djoussé, L., Riebman, J. B., GAGNON, D. R., & Joseph, J. (2020) · Figshare · doi:10.6084/m9.figshare.11972457
NOTI, S. (2021) · Electronic Theses and Dissertations Repository (University of Pisa)
Sydämen systolisen vajaatoiminnan lääkehoidon toteutuminen Tyks Sydänkeskuksessa vuosina 2020–2022
Saxberg, J. (2024) · UTUPub (University of Turku)
Ali, J. A., Mittal, B., Deeb, F. E., Semaan, C., & Sabbour, H. M. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0119
Landmark clinical trials shaping contemporary guideline-directed medical therapy for heart failure
Tkaczyszyn, M., Kapłon‐Cieślicka, A., Janiszewski, M., Klimczak‐Tomaniak, D., Jędrzejczyk‐Patej, E., Burchardt, P., Abdin, A., Böhm, M., Chioncel, O. D., Baudry, G., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag141
“5 However, the European Medicines Agency approved ivabradine for use in Europe in patients with HFrEF with LVEF ≤ 35% and in SR ≥ 75 b.p.m., because in this group ivabradine was associated with survival benefit in a secondary subgroup analysis of the SHIFT study 104 ( Table 5 and Figure 5 ).”
Self-citationImamura, T. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07975-3
Ivabradine in Heart Failure Treatment
Krstačić, G. (2015) · Cardiologia Croatica · doi:10.15836/ccar.2015.148
Metadata
- Authors
- Böhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- SUNY Downstate Health Sciences University (US)
- University of Glasgow (GB)
- Hospital Universitario La Paz (ES)
- University of Gothenburg (SE)
- Maria Cecilia Hospital (IT)
- Corresponding author
- Böhm, Michael
- Reil, Jan-Christian
- ORCID
- Venue
- Clinical Research in Cardiology
- Published
- 2012-05-11
- Volume
- 102
- Issue
- 1
- Pages
- 11-22
- ISSN
- 1861-0684 (ISSN-L)
- 1861-0692
- OpenAlex
- W2045247934
- Cited by
- 248
- References
- 18
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 15 · 2023: 15 · 2022: 13 · 2021: 16 · 2020: 19 · 2019: 19 · 2018: 18 · 2017: 16 · 2016: 34 · 2015: 15 · 2014: 19 · 2013: 27 · 2012: 10
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Clinical Research in Cardiology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- ivabradine, chronic heart failure, baseline heart rate, SHIFT trial, cardiovascular mortality, heart failure hospitalization, heart rate reduction, all-cause mortality
- MeSH terms
- Ivabradine, Aged, Anti-Arrhythmia Agents, Benzazepines, Chronic Disease, Double-Blind Method, Female, Heart Failure, Heart Rate, Hospitalization, Humans, Male, Middle Aged, Risk Factors, Time Factors, Proportional Hazards Models, Treatment Outcome, Disease Progression, Risk Assessment, Patient Selection, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.